Testing the Efficacy of the DETA-AP devices as part of treating patients having Pulmonary Tuberculosis (TB)
The aim of this clinical pilot study was to determine the efficacy of the Deta AP bioresonance devices with patients that had been clinically diagnosed with Pulmonary TB, including multiple drug-resistant TB.
The trials were conducted at the State Health Care Institution of the Yaroslavl Region Regional Clinical Hospital for Tuberculosis, Russia.
Twenty five patients having tuberculosis were tested, among them there were 11 women, 14 men and 9 of these patients had multiple drug-resistant tuberculosis.
The age of the men was from 24 to 56 years old, the women from 24 to 58 years old.
The Deta AP therapy programme “Tuberculosis” was run for the prescribed period of time, once per week for 30 days. Criteria for assessing the efficiency of treatment were clinical, radiological and bacteriological examinations.
Radiological improvements were observed in 18 cases (72%); a further 6 cases (24%) had no change and only 1 case got worse (4%).
According to the bacteriological examination, a complete eradication of the TB bacterium was seen in 12 cases (48%), BK (-) in 8 cases before and after the examination, with 4 patients that were still positive.
One patient had to terminate treatment after 4 sessions, as drug liver disease and hepato-renal syndrome developed.
It should be noted that all programmes of the devices are well-tolerated, and there were no adverse reactions to the treatment.
1. DETA-AP treatment is safe for TB infections.
2. The applied treatment protocols for TB should be further developed – increasing exposure time, multiple sessions, extending the duration of treatment from one month to 2-4 months.